drugset / Trial / NCT02496039

Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

NCT02496039

Phase 4 Terminated 5 enrolled Avanir Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.

Timeline

Start
2015-09
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 20 mg Oral
Subject Quinidine Small molecule 10 mg Oral

Indications